The race to produce a herpes virus vaccine heated up today with the announcement of a second mRNA-based clinical trial commencing.
Biopharmaceutical New Technologies (BioNTech) SE, a global leader in mRNA vaccines, announced that the first subject was dosed in a Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1.
Another mRNA Herpes Vaccine Candidate Launches
When Are Airports Busy in 2022
The Transportation Security Administration (TSA) recently answered a leading question most air travelers ask when preparing to travel over the 2022 holiday season.
The TSA announced that it expects travel volumes to be busiest on Dec. 22 and Dec. 30, 2022.
Additionally, the TSA suggests packing an extra dose of patience on those days!
As of December 20, 2022, TSA airport activity approached about 95% of 2019 volumes.
U.S. to Release Flu Meds From National Stockpile to Ease Shortages
Decision comes as the nation suffers from an unusually early and hard flu season, with about 9,300 deaths so far
Bivalent COVID-19 mRNA Booster Effective
Bivalent booster is effective against COVID-19 hospitalization in immunocompetent adults, seniors
2001 to 2021 Saw Decline in Physician Work Hours
However, trend offset by increase in advanced practice professionals weekly work hours